Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 7, 2009 Brian Orelli	Bristol-Myers Squibb: On the Patent Cliff's Edge Bristol-Myers Squibb changed its huge patent cliff into two smaller falls with a larger ledge in the middle.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool January 31, 2008 Brian Lawler	A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing.
The Motley Fool April 28, 2005 Stephen D. Simpson	Bristol-Myers: Hang in There Generics are wreaking havoc on growth, but patient investors can pin hopes on drugs now in the pipeline.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool July 29, 2004 Brian Gorman	Bristol-Myers Bottoming Out? The pharmaceutical company's expectations are in doubt, but investors might want to focus on its potential.
The Motley Fool October 8, 2008 Brian Orelli	Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states.
The Motley Fool February 29, 2008 Brian Lawler	FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder.
The Motley Fool March 27, 2008 Brian Lawler	Eli Lilly Hands Over Cold Cash Lilly loses to the state of Alaska in a courtroom battle over its top drug Zyprexa.
The Motley Fool May 30, 2008 Brian Lawler	Bristol-Myers' Cheap Pipeline Bet Bristol-Myers announces that it is acquiring development-stage drugmaker Kosan Biosciences for a net price of $190 million in cash.
The Motley Fool October 30, 2006 Brian Lawler	Sales Slow Down for Bristol-Myers Plavix isn't the only drug facing a challenging future. Losing patent protection and facing generic competition can be disastrous to sales and earnings if a pharmaceutical company doesn't have a way to drive revenue growth. Investors, take note.
The Motley Fool June 30, 2010 Brian Orelli	Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool January 27, 2005 Stephen D. Simpson	Generics Bout Gets Bloody Bristol-Myers Squibb struggles to keep growing amid patent expirations.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool December 14, 2004 Brian Gorman	Bristol-Myers' Smart Moves Although problems still hang over the company, Bristol-Myers is paving the way for recovery. In the meantime investors will surely be jittery.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.
The Motley Fool August 24, 2007 Brian Orelli	Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note.
The Motley Fool March 31, 2009 Brian Orelli	Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news.
The Motley Fool April 29, 2004 Bill Mann	Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses.
The Motley Fool March 5, 2010 Brian Orelli	How to Replace $6.1 Billion in Lost Revenue It's not easy, but Bristol-Myers will give it a shot.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool April 29, 2009 Brian Orelli	Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising.
The Motley Fool July 30, 2007 Brian Lawler	Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
Chemistry World October 26, 2012 Andrew Turley	Patent woes lead to sharp sales losses Financial results for the third quarter of 2012 from several big pharma companies reveal a dramatic loss of sales as patent protection for key drugs expires. It is an all too familiar story for the industry
The Motley Fool May 1, 2007 Brian Lawler	Bristol-Myers Stops Spinning in Place Bristol-Myers releases first-quarter financial results. Investors, take note.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool August 21, 2008 Brian Lawler	PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
IndustryWeek March 1, 2005	Pharmaceutical Misallocation Some 75% of surveyed pharmaceutical industry executives identified long-term resource allocation as their chief challenge.
The Motley Fool May 27, 2009 Brian Orelli	It's Approved! Now Back to Work Now that Bristol-Myers has received approval on its cancer drug Sprycel, it can get back to working on getting it out of its niche market and approved to treat other types of cancer.
The Motley Fool January 25, 2006 Stephen D. Simpson	Bristol-Myers Catches a Cold Tough days are coming, but so are promising new drugs. It's understandable why long-term investors might be willing to hold on and see how things work out.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool March 30, 2009 Brian Orelli	Here's Some Cash. Go Away. Bristol-Myers Squibb has to pay $2.1 million to settle a Federal Trade Commission investigation.
The Motley Fool September 13, 2006 Brian Lawler	What to Make of Bristol-Myers Take a good look at the industry to try to sort out the meaning of all the news and the rumors. Investing in a company based on a possible buyout is never a good idea when the possibility is based solely on rumors and analyst speculation.
Knowledge@Wharton	Bristol-Myers Squibb Illustrates Woes of Ailing Pharmaceutical Industry The once-mighty pharmaceutical industry, for years the nation's most profitable, has begun to show some cracks. But no major U.S. drug maker seems to be facing more problems than Bristol-Myers Squibb.
The Motley Fool October 28, 2005 Stephen D. Simpson	Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination.
The Motley Fool October 23, 2009 Brian Orelli	I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared.
The Motley Fool September 25, 2007 Billy Fisher	Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
The Motley Fool July 28, 2005 Stephen D. Simpson	Bristol-Myers' Road to Better Health Bristol-Myers looks toward 2007 and a resumption of real growth. For now, things could be a lot worse. At least investors can't say they're not getting paid to be patient.
The Motley Fool September 17, 2008 Brian Orelli	IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business.
The Motley Fool February 9, 2009 Robert Steyer	Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name.
The Motley Fool December 26, 2007 Brian Lawler	Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool September 11, 2008 Brian Lawler	ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet.